CombiMatrix 10-K 24 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 21, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'CombiMatrix Corp	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	11,063,246	'
Entity Public Float	'	'	$12,310,000
Amendment Flag	'false	'	'
Entity Central Index Key	'0001383183	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$12,289	$2,372
Short-term investments	1,747	'
Accounts receivable, net of allowance for doubtful accounts of $288 and $245	1,695	1,262
Supplies	171	465
Prepaid expenses and other assets	128	138
Total current assets	16,030	4,237
Property and equipment, net	581	666
Investments in unconsolidated subsidiaries and other	221	211
Patents and licenses, net	'	66
Total assets	16,832	5,180
Current liabilities:	'	'
Accounts payable, accrued expenses and other	1,367	1,222
Current portion, capital lease obligations	168	253
Warrants, net of $0 and $280 in issuance costs	568	4,204
Total current liabilities	2,103	5,679
Capital lease obligations, net of current portion	65	226
Total liabilities	2,168	5,905
Commitments and contingencies (Note 8)	'	'
Stockholders' equity (deficit):	'	'
Common stock; $0.001 par value; 25 million shares authorized; 9,870,838 and 1,511,133 shares issued and outstanding	10	2
Additional paid-in capital	95,098	67,106
Accumulated other comprehensive loss	-4	'
Accumulated deficit	-80,440	-68,227
Total stockholders' equity (deficit)	14,664	-1,119
Total liabilities and stockholders' equity (deficit)	16,832	5,180
Short-term Investments [Member]	'	'
Current assets:	'	'
Short-term investments	1,747	'
Series A Convertible Preferred Stock [Member]	'	'
Convertible preferred stock; $0.001 par value; 5 million shares authorized;	'	'
Convertible preferred stock	'	394
Series B Convertible Preferred Stock [Member]	'	'
Convertible preferred stock; $0.001 par value; 5 million shares authorized;	'	'
Convertible preferred stock	0	0
Series C Convertible Preferred Stock [Member]	'	'
Convertible preferred stock; $0.001 par value; 5 million shares authorized;	'	'
Convertible preferred stock	0	0
Series D Convertible Preferred Stock [Member]	'	'
Convertible preferred stock; $0.001 par value; 5 million shares authorized;	'	'
Convertible preferred stock	$0	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts (in Dollars)	$288	$245
Warrants, issuance costs (in Dollars)	0	280
Series A - stock issuance costs (in Dollars)	106	'
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	9,870,838	1,511,133
Common stock, shares outstanding	9,870,838	1,511,133
Series A Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	4,000	4,000
Preferred stock, shares issued	0	1,644
Preferred stock, shares outstanding	0	1,644
Series A - stock issuance costs (in Dollars)	$0	$101
Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	2,500	2,500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	12,000	12,000
Preferred stock, shares issued	2,201	0
Preferred stock, shares outstanding	2,201	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:	'	'
Royalties	$163,000	$180,000
Total revenues	6,367,000	5,350,000
Operating expenses:	'	'
Cost of services	3,527,000	2,702,000
Research and development	1,011,000	1,400,000
Sales and marketing	2,764,000	2,596,000
General and administrative	5,206,000	5,378,000
Patent amortization and royalties	254,000	266,000
Total operating expenses	12,762,000	12,342,000
Operating loss	-6,395,000	-6,992,000
Other income (expenses):	'	'
Interest income	5,000	1,000
Interest expense	-356,000	-179,000
Warrant derivative gains (charges	2,804,000	-2,357,000
Total other income (expense)	2,453,000	-2,535,000
Net loss	-3,942,000	-9,527,000
Net loss attributable to common stockholders	-12,213,000	-10,267,000
Basic and diluted net loss per share (in Dollars per share)	($1)	($8.75)
Basic and diluted net loss per share attributable to commo n stockholders (in Dollars per share)	($3.11)	($9.43)
Basic and diluted weighted average common shares outstanding (in Shares)	3,940,965	1,088,833
Diagnostics Services [Member]	'	'
Revenues:	'	'
Services	6,204,000	4,975,000
Clinical Trial Support Services [Member]	'	'
Revenues:	'	'
Services	'	195,000
Dividend Declared [Member] | Series A Convertible Preferred Stock [Member]	'	'
Other income (expenses):	'	'
Convertible preferred stock dividends	-247,000	-123,000
Convertible preferred stock dividends per share (in Dollars per share)	($0.06)	($0.11)
Dividend Declared [Member] | Series C Convertible Preferred Stock [Member]	'	'
Other income (expenses):	'	'
Convertible preferred stock dividends	-27,000	'
Convertible preferred stock dividends per share (in Dollars per share)	($0.01)	'
Deemed Dividend From Issuing Stock [Member] | Series A Convertible Preferred Stock [Member]	'	'
Other income (expenses):	'	'
Convertible preferred stock dividends	'	-617,000
Convertible preferred stock dividends per share (in Dollars per share)	'	($0.57)
Deemed Dividend From Issuing Stock [Member] | Series C Convertible Preferred Stock [Member]	'	'
Other income (expenses):	'	'
Convertible preferred stock dividends	-1,213,000	'
Convertible preferred stock dividends per share (in Dollars per share)	($0.31)	'
Deemed Dividend From Issuing Stock [Member] | Series B Convertible Preferred Stock [Member]	'	'
Other income (expenses):	'	'
Convertible preferred stock dividends	-417,000	'
Convertible preferred stock dividends per share (in Dollars per share)	($0.11)	'
Deemed Dividend From Issuing Stock [Member] | Series D Convertible Preferred Stock [Member]	'	'
Other income (expenses):	'	'
Convertible preferred stock dividends	($6,367,000)	'
Convertible preferred stock dividends per share (in Dollars per share)	($1.62)	'

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Net loss	($3,942)	($9,527)
Unrealized loss on available-for-sale securities	-4	'
Total comprehensive loss	($3,946)	($9,527)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' (Deficit) Equity (USD $)

Accrued [Member]

Accrued [Member]

Deemed Dividend From Issuing Stock [Member]

Deemed Dividend From Issuing Stock [Member]

Deemed Dividend From Issuing Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Retained Earnings [Member]

Retained Earnings [Member]

Retained Earnings [Member]

Retained Earnings [Member]

Retained Earnings [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Total

Retained Earnings [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Retained Earnings [Member]

Series A Convertible Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

USD ($)

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Series A Convertible Preferred Stock [Member]

USD ($)

USD ($)

Series A Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balances at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,000

'

'

'

'

'

$66,108,000

'

'

'

'

'

($57,960,000)

'

'

'

'

'

$8,150,000

Balances (in Shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,070,412

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split adjustment (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock, net of issuance costs

'

'

'

'

'

'

'

'

'

394,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock, net of issuance costs (in Shares)

'

'

'

'

'

'

'

'

'

2,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,871

'

'

'

'

'

Beneficial conversion feature on convertible preferred stock

'

'

'

'

'

'

'

'

'

-495,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

495,000

'

'

'

'

'

'

'

'

'

'

'

495,000

Conversion of convertible preferred stock to common stock (in Shares)

'

'

'

'

'

'

'

'

'

-855.54814

'

'

'

'

'

'

'

'

'

427,878

'

'

'

'

'

'

'

'

'

'

'

'

427,878

'

'

'

'

'

Dividends paid in common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

101,000

'

'

'

'

'

-101,000

'

'

'

'

'

'

Dividends paid in common stock (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,871

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends on convertible preferred stock

-22,000

-22,000

495,000

-617,000

-617,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash stock compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

402,000

'

'

'

'

'

'

'

'

'

'

'

402,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,527,000

'

'

'

'

'

-9,527,000

Balances at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

394,000

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

67,106,000

'

'

'

'

'

-68,227,000

'

'

'

'

'

-1,119,000

Balances (in Shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

1,644.45

'

'

'

'

'

'

'

'

'

1,511,133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock, net of issuance costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,769,000

2,139,000

10,720,000

'

'

'

'

'

'

'

'

'

1,769,000

2,139,000

10,720,000

'

'

Issuance of stock, net of issuance costs (in Shares)

'

'

'

'

'

'

'

'

'

'

1,610.40

2,400

12,000

'

'

130,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000

'

'

Beneficial conversion feature on convertible preferred stock

'

'

'

'

'

'

'

'

'

'

-417,000

-1,213,000

-6,367,000

'

'

'

'

'

'

'

'

417,000

1,213,000

6,367,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible preferred stock to common stock (in Shares)

'

'

'

'

'

'

'

'

-1,644.45

'

-1,610.40

-2,400

-9,799.30

'

822,421

535,392

839,864

4,756,946

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

839,864

'

'

'

Conversion of convertible preferred stock to common stock

'

'

'

'

'

'

'

'

-394,000

'

'

'

'

'

1,000

'

1,000

5,000

'

'

393,000

'

-1,000

-5,000

'

'

'

'

'

'

'

'

394,000

'

'

'

'

'

Dividends paid in common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,000

247,000

'

'

'

'

-27,000

-247,000

'

'

'

'

22,000

'

Dividends paid in common stock (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,141

50,307

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Series A common stock warrants

'

'

'

'

'

1,000

3,141,000

3,142,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Series A common stock warrants (in Shares)

'

'

'

'

'

1,209,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative warrant liability from warrant exercises

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,111,000

'

'

'

'

'

'

'

'

'

'

'

1,111,000

Dividends on convertible preferred stock

'

'

'

'

'

'

'

'

'

'

417,000

1,213,000

6,367,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-417,000

-1,213,000

-6,367,000

'

'

-247,000

'

'

'

'

'

Non-cash stock compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

432,000

'

'

'

'

'

'

'

'

'

'

'

432,000

Unrealized loss on available-for-sale securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,000

'

'

'

'

'

'

'

'

'

'

-4,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,942,000

'

'

'

'

'

-3,942,000

Balances at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

'

'

'

'

'

$95,098,000

($4,000)

'

'

'

'

($80,440,000)

'

'

'

'

'

$14,664,000

Balances (in Shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200.70

'

'

'

'

'

9,870,838

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balances at Feb. 25, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible preferred stock to common stock (in Shares)

'

'

'

'

'

'

'

1,209,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balances (in Shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balances at Feb. 28, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible preferred stock to common stock (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

535,392

'

'

'

'

Balances (in Shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Net loss	($3,942,000)	($9,527,000)
Adjustments to reconcile net loss to net cash flows from operating activities:	'	'
Depreciation and amortization	698,000	490,000
Stock compensation	432,000	402,000
Warrant derivative (gains) charges	-2,804,000	2,357,000
Provision for bad debts	290,000	276,000
Loss on disposal of fixed assets	49,000	'
Accounts receivable	-723,000	-76,000
Supplies, prepaid expenses and other assets	294,000	48,000
Accounts payable, accrued expenses and other	101,000	90,000
Net cash flows from operating activities	-5,605,000	-5,940,000
Investing activities:	'	'
Purchase of property and equipment	-304,000	-31,000
Purchase of available-for-sale investments	-1,750,000	'
Net cash flows from investing activities	-2,054,000	-31,000
Financing activities:	'	'
Net proceeds from exercise of common stock warrants	3,142,000	'
Repayment of capital lease obligations	-259,000	-121,000
Net cash flows from financing activities	17,577,000	1,958,000
Issuance costs relating to Series A convertible preferred stock	-106,000	'
Increase (decrease) in cash and cash equivalents	9,918,000	-4,013,000
Cash and cash equivalents, beginning	2,372,000	6,385,000
Unrealized loss on cash equivalents	-1,000	'
Cash and cash equivalents, ending	12,289,000	2,372,000
Cash paid in interest expense	54,000	25,000
Non-cash investing and financing activities:	'	'
Property and equipment purchased on capital leases	13,000	306,000
Make-whole Series A convertible preferred stock paid in common stock	247,000	101,000
Deemed dividends from issuing convertible preferred stock	7,997,000	617,000
Reclassification of derivative warrant liability from warrant exercises	1,111,000	'
Fair value of warrants issued in Series A convertible preferred stock offering	'	$2,127,000

Note_1_Description_of_Business

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1.     DESCRIPTION OF BUSINESS
	CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of. Acacia Research Corporation (“Acacia”), and in August 2007, we split-off from Acacia and became publicly traded on The Nasdaq Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.
	Description of the Company
	We provide valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care. We specialize in miscarriage analysis, prenatal and pediatric healthcare, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. We perform genetic testing utilizing a variety of advanced cytogenomic techniques, including microarray, standardized and customized FISH and high resolution karyotyping. We emphasize support for healthcare professionals, to ensure data understanding and communication of results to patients. We deliver high-technology driven answers, with a high degree of assistance for the ordering physician and staff.
	We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.
	Reverse Stock Split
	On December 4, 2012, we filed a Certificate of Amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse split of our common stock at a ratio of one-for-ten (the “Reverse Stock Split”), which became effective at the close of business on that day. As a result, each share of CombiMatrix common stock outstanding as of December 4, 2012 was automatically changed into one-tenth of a share of common stock. No fractional shares were issued in connection with the Reverse Stock Split, and cash paid to stockholders for potential fractional shares was insignificant. The number of shares of common stock subject to outstanding options, warrants and convertible securities were also reduced by a factor of ten as of December 4, 2012. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of our common stock were not affected by the Reverse Stock Split.
	Liquidity and Risks
	We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop new and improve existing commercial diagnostic testing services and related technologies. At December 31, 2013, we had cash, cash equivalents and short-term investments of $14.0 million and anticipate that our cash and cash equivalent balances will be sufficient to meet our cash requirements beyond 2014, thereby removing the substantial doubt that we can continue as a going concern beyond 2014. Our financial statements for the year ended December 31, 2012 were prepared assuming we would continue as a going concern. Our history of incurring net losses and net operating cash flow deficits led to the uncertainty regarding our ability to execute our business plans as of December 31, 2012, which also raised substantial doubt about our ability to continue as a going concern at December 31, 2012.
	In order for us to continue as a going concern beyond 2014 and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our shareholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans.
	Our business operations are also subject to certain risks and uncertainties, including:
		●	market acceptance of products and services;
		●	technological advances that may make our technologies and services obsolete or less competitive;
		●	increases in operating costs, including costs for supplies, personnel and equipment;
		●	the availability and cost of capital; and
		●	governmental regulation that may restrict our business.
	Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned technologies or services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Accounting Principles and Fiscal Year End. The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”). We have a December 31 year-end.
	Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Basis of Presentation and Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the years ended December 31, 2013 and 2012, net positive revenue adjustments were $607,000 and $570,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable.
	Clinical trials support services revenue is recognized when the related support services have been delivered to and accepted by the customer. Royalty revenue is recognized in the period when earned.
	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchaed with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statement of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.
	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		●	Level 1:	Observable market inputs such as quoted prices in active markets;
		●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, such as quoted prices for similar assets or liabilities; and
		●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash and money market funds within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
	Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables by payor class to assess our allowance at each period end. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor. Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.
	Supplies. Supplies inventory, which consists primarily of raw materials to be used in the production of the arrays we use for our tests, is stated at the lower of cost or market using the first-in, first-out method.
	Property and Equipment. Property and equipment is recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Disposals are removed at cost less accumulated depreciation or amortization and any gain or loss from disposition is reflected in the consolidated statement of operations in the period of disposition. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Laboratory equipment (years)		3	to	5
	Furniture and fixtures (years)		5	to	7
	Computer hardware and software (years)			3
	Leasehold improvements		Lesser of lease term or useful life of improvement
	Certain leasehold improvements, furniture and equipment held under capital leases are classified as property and equipment and are amortized over their useful lives using the straight-line method. Lease amortization is included in depreciation expense.
	Stock-Based Compensation. The compensation cost for stock-based awards to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award), which is generally three years. The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.
	The weighted average assumptions used to estimate the fair value of awards granted for the periods presented are noted in the table below. Expected volatility is based on the separate historical volatility of the market prices of our common stock. The risk-free rate for the expected term, using the simplified method, of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
			For the Years Ended
			December 31,
			2013			2012
	Risk free interest rate			1.7	%		1.3	%
	Volatility			106	%		78.5	%
	Expected term (years)		6.3			6.3
	Expected dividends			0	%		0	%
	Stock-based compensation expense for 2013 and 2012 attributable to our functional expense categories were as follows (in thousands):
			For the Years Ended
			December 31,
			2013			2012
	Cost of products and services		$	7		$	5
	Research and development			-			7
	Sales and marketing			14			4
	General and administrative			411			386
	Total non-cash stock compensation		$	432		$	402
	Research and Development Expenses. Prior to launching a new test or modifying an existing test, extensive laboratory validations consistent with the various regulations that govern our industry must be performed.  As a result, research and development expenses include labor, laboratory supplies, and other development costs required to maintain and improve our existing suite of diagnostic test offerings as well as to investigate and develop new tests.  Costs to acquire technologies which are utilized in research and development and which have no alternative future use are expensed when incurred. Software developed for use in our services is expensed as incurred until both (i) technological feasibility for the software has been established and (ii) all research and development activities for the other components of the system have been completed. We believe these criteria are met after we have received evaluations from third-party test sites and completed any resulting modifications to the services. Expenditures to date have been classified as research and development expense.
	Advertising. Costs associated with marketing and advertising of our services are expensed as incurred. For the years ended December 31, 2013 and 2012, we incurred marketing and advertising expenses of $249,000 and $312,000, respectively.
	Income Taxes. We recognize income taxes on an accrual basis based on tax positions taken or expected to be taken in our tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however.
	Other Comprehensive Loss. Components of comprehensive loss include unrealized gains and losses on available-for-sale securities and are included in the consolidated statements of comprehensive loss.
	Segments. We have determined that we operate in one segment for financial reporting purposes.
	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase CombiMatrix stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
			For the Years Ended
			December 31,
			2013			2012
	Common stock options			639,019			161,933
	Common stock warrants			7,623,677			1,219,479
	Series A preferred stock convertible into common stock			-			822,431
	Series D preferred stock convertible into common stock			1,068,297			-
	Excluded dilutive securities			9,330,993			2,203,843
	Recent Accounting Pronouncements. In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Income Taxes (Topic 740), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” to eliminate diversity in practice. Under this ASU, an unrecognized tax benefit, or a portion of an unrecognized tax benefit that exists at the reporting date, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if certain criteria are met. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2013 with early adoption permitted. We do not believe the adoption of this ASU will have a material impact on our consolidated financial statements.
	In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income or loss on the respective line items in net income or loss. The new accounting guidance does not change the items that must be reported in other comprehensive income or loss or when an item of other comprehensive income or loss must be reclassified to net income or loss. The guidance is effective prospectively for fiscal years beginning after December 15, 2012 and we were required to adopt these new provisions during the first quarter of 2013. As the guidance requires additional presentation only, there was no impact to our consolidated results of operations or financial position.

Note_3_Cash_and_ShortTerm_Inve

Note 3 - Cash and Short-Term Investments	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents Disclosure [Text Block]	'
	3.      CASH AND SHORT-TERM INVESTMENTS
	As of December 31, 2013, we held $12.3 million in cash and cash equivalents and $1.7 million of short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2013 (in thousands):
		As of December 31, 2013
		Cost		Unrealized		Unrealized			Fair Value
				Gain		Loss
	Cash and money market securities	$	11,290	$	-	$	-		$	11,290
	Certificates of deposit		2,750		-		(4	)		2,746
		$	14,040	$	-	$	(4	)	$	14,036
	Included in cash and cash equivalents	$	12,290	$	-	$	(1	)	$	12,289
	Included in short-term investments		1,750		-		(3	)		1,747
		$	14,040	$	-	$	(4	)	$	14,036
	There were no realized gains or losses for the year ended December 31, 2013.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	4.     FAIR VALUE MEASUREMENTS
	The following table summarizes, for each major category of financial assets or liabilities measured on a recurring basis, the respective fair value at December 31, 2013 and 2012, and the classification by level of input within the fair value hierarchy defined above (in thousands):
					Fair Value Measurements
	31-Dec-13	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	8,263		$	7,264	$	999	$	-
	Short-term investments		1,747			-		1,747		-
	Total	$	10,010		$	7,264	$	2,746	$	-
	Liabilities:
	Derivative warrant liability	$	568		$	-	$	-	$	568
					Fair Value Measurements
	31-Dec-12	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	14		$	14	$	-	$	-
	Liabilities:
	Derivative warrant liability	$	4,483		$	-	$	-	$	4,483
	The following table is a reconciliation of financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2013 (in thousands):
		Derivative Warrant Liability
	Balance, December 31, 2012	$	4,483
	Changes in fair value		(2,804	)
	Reclassifications		(1,111	)
	Balance, December 31, 2013	$	568
	The fair value of the derivative warrant liability is based on Level 3 inputs. For this liability, we developed our own assumptions that do not have observable inputs or available market data to support the fair value recorded. See Note 10 for further discussion of the derivative warrant liability.

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	5.     PROPERTY AND EQUIPMENT
	Property and equipment consists of the following (in thousands):
		December 31,
		2013			2012
	Laboratory equipment		1,737		$	1,745
	Furniture and fixtures		225			103
	Computer hardware and software		42			214
	Leasehold improvements		279			289
			2,283			2,351
	Less - accumulated depreciation and amortization		(1,702	)		(1,685	)
		$	581		$	666
	Depreciation and amortization expense was $352,000 and $276,000 for the years ended December 31, 2013 and 2012, respectfully. The net book value of assets under capital lease obligations was $246,000 and $523,000 as of December 31, 2013 and 2012, respectively.

Note_6_Balance_Sheet_Component

Note 6 - Balance Sheet Components	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
	6.     BALANCE SHEET COMPONENTS
	Accounts payable, accrued expenses and other accrued expenses consist of the following (in thousands):
		December 31,
		2013		2012
	Accounts payable	$	636	$	610
	Payroll and other employee benefits		353		324
	Accrued vacation		144		143
	Deferred rent		-		4
	Royalties		211		106
	Other accrued expenses		23		35
		$	1,367	$	1,222

Note_7_Income_Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	7.     INCOME TAXES
	The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred assets and liabilities consist of the following (in thousands):
		December 31,
		2013			2012
	Deferred tax assets:
	Deferred settlement costs	$	1,215		$	1,574
	Stock-based compensation		423			428
	Accrued liabilities and other		500			485
	Net operating loss carryforwards and credits		61,756			59,173
	Total deferred tax assets		63,894			61,660
	Less: valuation allowance		(63,944	)		(61,620	)
	Deferred tax assets, net of valuation allowance		(50	)		40
	Deferred tax liabilities:
	Depreciation and amortization		50			(40	)
	Net deferred tax liability	$	-		$	-
	A reconciliation of the federal statutory income tax rate and the effective income tax rate is as follows:
		December 31,
		2013			2012
	Statutory federal tax rate		(34	%)		(34	%)
	Impact on state tax rates		(7	%)		(5	%)
	Warrant valuation		(22	%)		9	%
	Cancellation of vested non-qualified stock options		1	%		9	%
	Valuation allowance		59	%		20	%
	Other non deductible permanent items		3	%		1	%
			0	%		0	%
	At December 31, 2013 and 2012, we had net deferred tax assets totaling approximately $63.9 million and $61.7 million, respectively. These assets are offset by valuation allowances due to our determination that the criteria for asset recognition have not been met, as well as by deferred tax liabilities. At December 31, 2013, we had federal net operating loss carryforwards of approximately $160 million, which begin to expire in 2017 through 2032. In addition, we have tax credit carryforwards of approximately $5.2 million. Utilization of net operating loss carryforwards and tax credit carryforwards are subject to the “change of ownership” provisions under Section 382 of the Internal Revenue Code. The amount of such limitations has not been determined. Also, given that our net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which we operate. We have no unrecognized tax benefits as of December 31, 2013 and 2012.

Note_8_Commitments_and_Conting

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8.     COMMITMENTS AND CONTINGENCIES
	Leases
	We have entered into a non-cancelable operating lease for approximately 12,200 square feet of office and laboratory facilities in Irvine, California with a lease term through January 2015.
	At December 31, 2013, we had eleven capital leases for laboratory equipment with original purchase amounts totaling $435,000 and with useful lives of five years. As of December 31, 2013, the remaining lease obligations (including interest charges) were $259,000 with minimum future lease payments shown below. The weighted average interest rate on the capital lease obligations was 13.5%, based on remaining lease obligations as of December 31, 2013. The fair value of the capital lease obligations was not significantly different from their carrying amounts for all periods presented.
	Future minimum lease payments for all of our facilities and leased equipment are as follows (in thousands):
	Years ending December 31:
		Operating  Leases		Capital Leases			Total
	2014	$	161	$	188		$	349
	2015		13		43			56
	2016		-		25			25
	2017		-		3			3
	2018		-		-			-
	Total minimum lease payments	$	174		259		$	433
	Less- imputed interest				(26	)
	Present value of capital lease obligations				233
	Less- current portion				(168	)
	Capital lease obligations, net of current portion			$	65
	Rent expense for the years ended December 31, 2013 and 2012 was $297,000 and $302,000, respectively.
	Executive Severance
	We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (the “Severance Plan”) that affects certain of our senior management-level employees who are classified as “Section 16 Officers” of the Company.  Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary; (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time.  Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code.  The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors.  In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements.
	Litigation
	On September 30, 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $100,000 in each of the years ended December 31, 2013 and 2012, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.
	On February 14, 2011, Relator Michael Strathmann (“Strathmann”) served us with a complaint (“the Complaint”) filed in the Superior Court of the State of California for the County of Orange. The Complaint alleged that we submitted false and fraudulent insurance claims to National Union Fire Insurance Company of Pittsburgh, PA in connection with a prior lawsuit that was settled with Nanogen, Inc., thereby allegedly violating the California Insurance Fraud Prevention Act, and sought penalties and unspecified treble damages. On May 4, 2011, the Superior Court dismissed the Complaint by ordering that it be stricken for violation of the California Anti-SLAPP statute, which prevents plaintiffs from filing abusive lawsuits against public policy. On June 15, 2011, Strathmann filed a Notice of Appeal with the California Court of Appeals, appealing the granting of the Motion to Strike. Subsequently, Strathmann filed a Notice of Appeal of the award of attorneys’ fees against him. On October 24, 2012, the California Court of Appeals reversed the Superior Court’s dismissal, finding that the anti-SLAPP statute was not applicable and remanding the case to the Superior Court. Strathmann filed an Amended Complaint, and we have filed our Answer to that pleading. On February 14, 2014, we filed a Motion for Summary Judgment, requesting that the Court enter judgment in our favor without trial. That Motion is to be heard by the Court on April 30, 2014. In the event that the Motion is not successful, then trial has been set for June 9, 2014, in the Orange County Superior Court. While discovery has commenced in the case, and we believe that there is no merit to Strathmann’s claims and intend to vigorously defend against them, there can be no assurance that we will ultimately be successful. No contingent liability has been recognized due to the lack of specificity relating to the damages being sought by Strathmann and management’s assessment that the likelihood of a materially unfavorable outcome is remote.
	From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

Note_9_Retirement_Savings_Plan

Note 9 - Retirement Savings Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	9.     RETIREMENT SAVINGS PLAN
	We have an employee savings and retirement plan under section 401(k) of the Internal Revenue Code (the “Retirement Plan”). The Retirement Plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the Retirement Plan, subject to certain guidelines issued by the Internal Revenue Service. We may contribute to the Retirement Plan at the discretion of our board of directors. There were no contributions made by us during any of the years presented.

Note_10_Stockholders_Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	10. STOCKHOLDERS’ EQUITY
	Series A Convertible Preferred Stock Financing
	On September 28, 2012 (the “Commitment Date”), we entered into a securities purchase agreement with certain accredited investors (the “Series A Investors”), pursuant to which we sold and issued 1,050.70039 shares of newly created Series A 6% Convertible Preferred Stock (the “Series A Stock”) to the Series A Investors at a purchase price of $1,000 per share in an initial closing that occurred on October 1, 2012 (the “Series A First Closing”), and we sold and issued 1,449.29961 additional shares of Series A Stock on December 6, 2012 to the Series A Investors at a purchase price of $1,000 per share after stockholder approval was obtained on November 29, 2012 (the “Series A Second Closing”) (combined, the “Series A Financing”). After certain offering-related costs were incurred, the net proceeds received by us from the Series A Financing were $2.0 million. As a result of the Series A Second Closing, the conversion price for the Series A Stock was set to $1.9995 per share, or the equivalent of 1.25 million shares of common stock issuable upon conversion of all Series A Stock. We filed resale registration statements on Form S-3 related to the Series A financing, which have been declared effective by the SEC. Until all Series A Investors no longer hold Series A warrants to purchase common stock: (i) we may not sell any variable rate securities or dilutive securities except for certain exempt issuances; (ii) if we enter into a subsequent financing on more favorable terms than the Series A Stock financing, then the agreements between us and the Series A Investors will be amended to include such more favorable terms; and (iii) we may not sell securities at an effective price per share less than $4.91 except for certain exempt issuances, unless waivers from the Series A Investors are obtained.
	Holders of the Series A Stock were entitled to receive accruing dividends at the annual rate of 6%, payable semi-annually. Upon conversion of Series A Stock into common stock, we paid to each holder of Series A Stock converting to common stock, as a “make-whole” payment in common stock, an amount equal to $118 per $1,000 of stated value of Series A Stock so converted, less the aggregate amount of dividends previously paid on such converting Series A Stock. During December 2012, the Series A Investors converted 855.54814 shares of Series A Stock into 427,878 shares of common stock. In addition, 12,871 shares of common stock were issued to the Series A Investors in payment of the make-whole dividends related to the Series A Stock conversions. On January 4, 2013, accrued Series A dividends of $22,000 were paid by issuing 4,164 shares of common stock to the Series A Investors. During the first quarter of 2013, the Series A Investors converted all of the remaining 1,644.45186 shares of Series A Stock into 822,421 shares of common stock. In addition, 50,307 shares of common stock were issued to the Series A Investors in payment of the make-whole and accrued dividends related to the Series A Stock conversions. The combination of make-whole and accrued dividends paid in shares of common stock for the twelve months ended December 31, 2013 was $247,000.
	In addition to the issuance of the Series A Stock, at the Series A First Closing, we issued warrants to purchase 213,945 shares of common stock to the Series A Investors. These warrants have a term of 5.5 years and initially were to become exercisable six months from the Series A First Closing, with an initial exercise price of $9.50 per share. At the Series A Second Closing, we issued warrants to purchase 724,825 shares of common stock to the Series A Investors. These warrants have a term of 5.5 years and initially were to become exercisable six months from the Series A Second Closing, with an initial exercise price of $2.364 per share (collectively, the “Series A Warrants”). The exercise price of the Series A Warrants and the number of shares of common stock underlying the Series A Warrants are subject to full-ratchet anti-dilution adjustments in the event we issue securities, other than certain excepted issuances, at a price below the then current exercise price of the Series A Warrants. On February 26, 2013, we entered into an agreement with the Series A Investors to modify the Series A Warrants such that they would become immediately exercisable as of February 22, 2013 (the “Modification Date”). Since the Modification Date through December 31, 2013, 1,209,634 shares of common stock have been issued from exercises of the Series A Warrants, resulting in proceeds to the Company of $3.1 million. See discussion below regarding further adjustments to the Series A Warrants as a result of the Series B, C and D financings executed during 2013.
	We account for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to our own stock. The Series A Warrants issued to the Series A Investors contain such provisions, thus requiring us to treat them as derivative financial instruments, to be recorded at fair value at issuance and subsequently adjusted to fair value at each reporting date, with the corresponding adjustment reflected as a non-operating credit / charge in the consolidated statement of operations. During 2013, we valued the Series A Warrants using the Monte-Carlo simulation method using the following assumptions at each valuation date: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the remaining Series A Warrant terms of 5.0 to 4.3 years; (iii) historical volatilities commensurate with the term of the remaining Series A Warrants of between 114.5% to 126.5%; (iv) risk-free interest rates commensurate with the term of the remaining Series A Warrants of 0.8% to 1.4%; and (v) simulated anti-dilution impact assuming various probabilities that we will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise price during the Series A Warrant terms. The result of these valuation simulations was to initially value the Warrants issued at a combined $2.1 million derivative liability, with the residual value allocated to the Series A preferred stock. Subsequently, the fair value of the warrants increased to $4.5 million at December 31, 2012, resulting in $2.4 million of warrant derivative charges recognized during the fourth quarter of 2012. During 2013, the warrant derivative liability decreased due primarily to lower stock prices as well as from Series A Warrant exercises, resulting in a net gain of $2.8 million and a reclassification to additional paid-in capital of $1.1 million, respectively.
	During 2012, we valued the Series A Warrants using the Monte-Carlo simulation method using the following assumptions at each valuation date: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the individual Series A Warrant terms ranging from 5.3 years to 5.5 years; (iii) historical volatilities commensurate with the term of the Series A Warrants ranging from 65.6% to 103.9%; (iv) risk-free interest rates commensurate with the term of the Series A Warrants ranging from 0.7% to 0.8%; and (v) simulated anti-dilution impact assuming various probabilities that the Company will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise prices during the Series A Warrant terms. The result of these valuation simulations was to initially value the Series A Warrants issued at a combined $2.1 million derivative liability, with the residual value of $495,000 allocated to the Series A Stock. Because the value of the Series A Warrants issued at the First Closing exceeded the consideration paid by Investors by $123,000, this amount was recorded as a deemed dividend charged to retained earnings at the First Closing. Subsequently, the fair value of the warrants increased to $4.5 million, resulting in $2.4 million of non-operating, warrant derivative charges recognized for the period ended December 31, 2012.
	Offering-related costs that were accrued or paid as of and for the period ending December 31, 2012 of $527,000 were allocated between the Series A Warrants and Series A Stock on a pro-rata basis, resulting in $427,000 allocated to the Series A Warrants and $101,000 allocated to the Series A Stock. Offering-related costs allocated to the Series A Warrants are being amortized over the Series A Warrant exercise restriction period of six months from issuance of the Series A Warrants, which resulted in $147,000 of additional interest expense charges in the period ended December 31, 2012. The remaining $280,000 of unamortized costs were expensed during the first three months of 2013 and charged to interest expense.
	Series B Convertible Preferred Stock Financing
	On March 19, 2013, we entered into a securities purchase agreement (the “Series B Purchase Agreement”) with an existing institutional investor (the “Series B Investor”) to purchase 130,000 shares of common stock at a price of $3.05 per share and approximately 1,610.4 units consisting of, in the aggregate, Series B 6% convertible preferred stock (the “Series B Stock”) and warrants to purchase up to 275,000 shares of common stock at an exercise price of $3.49 per share (the “Series B Warrants”) in a registered direct offering (the “Series B Financing”) of securities sold off of our existing shelf registration statement on Form S-3 (File No. 333-176372). The Series B Financing closed on March 20, 2013 (the “Series B Closing”). The Series B Stock and Series B Warrants were sold in multiples of fixed combinations, with each fixed combination consisting of one share of Series B Stock and a Series B Warrant to purchase approximately 171 shares of common stock. Each fixed combination of Series B Stock and Series B Warrants was sold at a price of $1,000. The Series B Stock was initially convertible into an aggregate of 528,000 shares of common stock at an initial conversion price of $3.05 per share. The Series B Warrants were not exercisable for six months from the Series B Closing, and the Series B Stock accrued dividends at an annual rate of 6% beginning six months after the Series B Closing, assuming the Series B Stock had not been converted by that time. Upon the Series B Closing, we received proceeds of $1.8 million, net of placement agent fees and other related paid and accrued costs. Given that the effective conversion price of the Series B Stock was below the closing market price of our common stock at the time of the Series B Closing, we recognized a beneficial conversion feature in the amount of $417,000. Since the Series B Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.
	The Series B Warrants have a 5.5 year term as well as a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series B Warrants, and are not exercisable for the first six months following issuance. The Series B Warrants are not subject to price anti-dilution protection.
	The Series B Investor agreed to be subject to a blocker that (i) would prevent its common stock ownership at any given time from exceeding 4.99% (which may be increased, but not above 9.99%) of our outstanding common stock; or (ii) would prevent us from issuing any shares of common stock to the Series B Investor upon the conversion by such Series B Investor of Series B Stock if the issuance of such shares to the Series B Investor, when aggregated with all other shares of common stock sold to the Series B Investor under the Series B Purchase Agreement together with all shares of common stock issued upon the conversion of Series B Stock, would result in the total issuance of common stock to exceed 19.99% of our outstanding common stock, without first obtaining the approval of our stockholders. We obtained stockholder approval at our June 27, 2013 Annual Stockholders’ Meeting for the terms of the Series B Stock and the issuance and delivery in the aggregate of that number of shares of common stock exceeding 19.99% of the outstanding shares of common stock upon conversion of the Series B Stock. Since the Series B Closing through December 31, 2013, the Series B Investor has converted all of the Series B stock into 535,392 shares of common stock. See discussion below regarding additional adjustments to the Series B Stock as a result of the Series C Financing. Also, as a result of the Series B Financing, the exercise price of the Series A Warrants issued in the Series A First Closing automatically ratcheted down by their terms from their original exercise price of $9.50 per share to an adjusted exercise price of $3.05 per share, and the underlying shares exercisable as of the Series B Closing were automatically increased from 213,935 shares to 666,375 shares at that time.
	Series C Convertible Preferred Stock Financing
	On May 3, 2013, we entered into a securities purchase agreement (the “Series C Purchase Agreement”) with certain accredited investors (the “Series C Investors”), pursuant to which we sold and issued 1,200 shares of our newly created Series C 6% convertible preferred stock (the “Series C Stock”) to the Series C Investors at a purchase price of $1,000 per share in an initial closing that occurred on May 6, 2013 (the “Series C First Closing”), and we sold and issued 1,200 additional shares of Series C Stock to the Series C Investors on June 28, 2013 at a purchase price of $1,000 per share after stockholder approval was obtained on June 27, 2013 (the “Series C Second Closing”) (combined, the “Series C Financing”). After certain offering-related costs, the net proceeds from the Series C Financing were $2.14 million.
	As a result of the Series C Second Closing, the conversion price for the Series C Stock was set to $2.85759 per share, or the equivalent of 839,864 shares of common stock issuable upon conversion of all Series C Stock. The conversion price of the Series C Stock was also subject to proportional adjustment for stock splits, stock dividends, recapitalizations and the like. The Series C Stock earned 6% annual dividends. Accrued dividends are payable semi-annually, and also on the date of conversion of any Series C Stock, in cash or, subject to certain conditions and at our election, in shares of common stock. If the dividends are paid in shares of common stock, the number of shares of common stock comprising the dividend on each share of Series C Stock will be valued at a 20% discount to the average of the daily volume weighted average price for the five-day trading period immediately prior to the dividend payment date. Given that the effective conversion price of the Series C Stock was below the closing market price of our common stock at the time of both of the Series C closings, we recognized beneficial conversion features in the amount of $1.2 million, which were limited to and reduced the net proceeds allocated to the Series C Stock. Since the Series C Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.
	Also as a result of the Series C Second Closing, the exercise price of the Series A Warrants issued in the Series A First Closing automatically ratcheted down by their terms from their most recent exercise price of $3.05 per share to an adjusted exercise price of $2.86 per share, and the underlying shares exercisable as of the Series C Second Closing were automatically increased from 441,566 shares to 470,907 shares. In addition, the conversion price of the Series B Stock automatically ratcheted down by their terms from $3.05 per share to an adjusted conversion price of $2.85759 per share, and the underlying shares issuable from conversion of Series B Stock as of the Series C Second Closing were automatically increased from 109,837 shares to 117,231 shares.
	In addition to the issuance of the Series C Stock, we issued warrants at the Series C First Closing to purchase 491,803 shares of our common stock with an exercise price of $3.77 per share, and. at the Series C Second Closing, we issued additional warrants to purchase 491,803 shares of our common stock with an exercise price of $3.55 per share (collectively, the “Series C Warrants”). The exercise price of the Series C Warrants issued equaled 110% of the market value (as defined by Nasdaq rules) of one share of common stock on each closing date. The Series C Warrants have a 5.5 year term, were not exercisable for the first six months following issuance and include a cashless exercise provision, which is only applicable if the common stock underlying the Series C Warrants was not subject to an effective registration statement or otherwise cannot be sold without restriction pursuant to Rule 144.
	The common stock underlying the Series C Stock and Series C Warrants were initially unregistered under the Securities Act of 1933. In connection with the Series C Financing, however, we entered into a registration rights agreement with the Series C Investors (the “Registration Rights Agreement”). The Registration Rights Agreement required us to file registration statements with the SEC registering for resale: (i) the shares of common stock issuable upon conversion of the Series C Stock; (ii) the shares of common stock issuable as dividends on the Series C Stock; (iii) the shares of common stock issuable upon exercise of the Series C Warrants; and (iv) any additional shares of common stock issuable in connection with any anti-dilution provisions associated with the Series C Stock. We filed registration statements relating to both of the Series C closings, and both registration statements have been declared effective by the SEC. Under the terms of the Registration Rights Agreement, we are obligated to maintain the effectiveness of the resale registration statements until all securities registered thereunder are sold or otherwise can be sold without restriction pursuant to Rule 144. The Registration Rights Agreement includes liquidated damages provisions in the event we fail to file or maintain the effectiveness of the registration statements. We do not plan, nor are we obligated, to register the Series C Stock or the Series C Warrants.
	For the year ended December 31, 2013, the Series C Investors have converted all of their shares of Series C stock into 839,864 shares of common stock.
	Series D Convertible Preferred Stock Financing
	On December 20, 2013 (the “Series D Closing”), we closed an underwritten public offering (the “Series D Offering”) and issued 12,000 units of securities to investors, with each unit consisting of: (i) one share of Series D preferred stock (“Series D Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $2.06, which was 72.5% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on December 16, 2013, the date we executed the underwriting agreement (“UA date”); and (ii) one warrant exercisable for 485.4369 shares of our common stock, at an exercise price per share equal to $3.12 (“Series D Warrants”), which was 110% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on the UA date. The shares of common stock underlying the Series D Stock and Series D Warrants were registered on Form S-1 (File No. 333-191221), which was declared effective by the SEC on December 16, 2013. The Series D Stock was immediately convertible and the Series D Warrants were immediately exercisable for shares of common stock and have a term of five years. In total, there were 5,825,243 shares of common stock issuable upon conversion of the Series D Stock and up to 5,825,243 shares of common stock issuable upon exercise of the Series D Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds of $12 million at the Series D Closing. After certain offering-related costs paid to the underwriters and others at the closing and through February 2014, net proceeds received by us were $10.7 million. As of December 31, 2013, 9,799.3 shares of Series D Stock have converted into 4,756,946 shares of common stock. Subsequent to December 31, 2013 and through the date of this report, all of the remaining Series D Stock has converted into an additional 1,068,297 shares of common stock. Also as a result of the Series D Offering, the exercise price of the then-outstanding Series A Warrants automatically ratcheted down by their terms from their original exercise price of $2.86 per share to an adjusted exercise price of $2.06 per share, and the underlying shares exercisable was automatically increased by 81,910 shares. A registration statement on Form S-3 has been filed in order to register these shares as per the terms of our original Series A offering documents.
	Warrants
	Outstanding warrants to purchase our common stock are as follows:
			Shares of Common Stock Issuable from Warrants
			Outstanding as of December 31,				Exercise
			2013		2012		Price			Expiration
	Liability-classified warrants:
	Oct-12			292,817		213,945		$2.06	-1	Apr-18
	Dec-12			-		724,825		$2.36		Jun-18
				292,817		938,770
	Equity-classified warrants:
	Dec-13			5,825,243		-		$3.12		Dec-18
	Jun-13			491,803		-		$3.55		Dec-18
	May-13			491,803		-		$3.77		Nov-18
	Mar-13			275,000		-		$3.49		Sep-18
	Apr-11			131,047		131,047		$21.40		Apr-16
	Oct-09			3,000		3,000		$77.80		Oct-14
	May-09			2,967		2,967	$75.00	-	90	May 2014 - July 2014
	May-09			109,997		109,997		$90.00		May-14
	Jul-08			-		33,698	$118.70	-	136.5	Jul-13
	Total			7,330,860		280,709
	Total - all warrants			7,623,677		1,219,479
	-1	Prior to the anti-dilution adjustments which occurred on March 20, 2013, June 28, 2013 and December 20, 2013, these warrants had an initial exercise price of $9.50 per share.

Note_11_Stock_Options

Note 11 - Stock Options	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	11.     STOCK OPTIONS
	Our employees participate in the CombiMatrix Corporation 2006 Stock Incentive Plan (the “CombiMatrix Plan”), which was approved by our board of directors in 2006. In addition, during 2005, the board of directors of our wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc., approved the CombiMatrix Molecular Diagnostics 2005 Stock Award Plan (the “CMDX Plan”). Our board of directors believes that granting employees stock-based awards from the CombiMatrix Plan is in the best interest of our Company and our stockholders. No awards have been granted to the CMDX Plan since 2010, and it is no longer being utilized.
	CombiMatrix Corporation 2006 Stock Incentive Plan
	The CombiMatrix Plan is administered by the Compensation Committee (the “Committee”) of our Board of Directors. The Committee determines which eligible individuals are to receive option grants or stock issuances under the CombiMatrix Plan, the time or times when the grants or issuances are to be made, the number of shares subject to each grant or issuance, the status of any granted option as either an incentive stock option or a non-statutory stock option under the federal tax laws, the vesting schedule to be in effect for the option grant or stock issuance and the maximum term for which any granted option is to remain outstanding.
	The CombiMatrix Plan is divided into three separate equity incentive programs: a discretionary option grant / stock appreciation right program, a stock issuance program, and an automatic option grant program for outside directors. To date, the discretionary option grant program has been the primary program used in awarding stock-based compensation. Under the discretionary option grant program, the Committee may grant non-statutory options to purchase shares of CombiMatrix stock to eligible individuals in our employ (including employees, non-employee board members and consultants) at an exercise price not less than 100% of the fair market value of those shares on the grant date, and incentive stock options to purchase shares of CombiMatrix stock to eligible employees at an exercise price not less than 100% of the fair market value of those shares on the grant date. Options are generally exercisable over a three- or four-year vesting term following the date of grant and expire ten years after the grant date. The authorized number of shares of common stock subject to the CombiMatrix Plan increases by 3% of the total number of CombiMatrix common stock outstanding at the end of each calendar year. At December 31, 2013, there were approximately 856,000 authorized shares available under the CombiMatrix Plan, with approximately 203,000 shares available for grant.
	The following is a summary of the stock option activities under the CombiMatrix Plan for 2013 and 2012:
		Shares			Weighted Average Price		Weighted Contractual Term (years)		Aggregate Intrinsic Value ('000s)
	Balance at December 31, 2011		223,243		$	48.69		7.8	$	6
	Granted		60,000		$	10
	Exercised		-		$	-
	Forfeited		(52,933	)	$	22.47
	Cancelled		(66,377	)	$	67.91
	Balance at December 31, 2012		163,933		$	35.21		7.3	$	23
	Granted		502,586		$	3.29
	Exercised		-		$	-
	Forfeited		(13,750	)	$	9.68
	Cancelled		(13,750	)	$	28.94
	Balance at December 31, 2013		639,019		$	10.79		8.7	$	1
	Exercisable at December 31, 2012		86,335		$	53.44		5.7	$	-
	Exercisable at December 31, 2013		98,259		$	47.75		6	$	-
	Information related to options granted under the CombiMatrix Plan for 2013 and 2012 is as follows:
		December 31,
		2013			2012
	Weighted average fair values of options granted	$	2.39		$	6.23
	Options granted with exercise prices:
	Greater than market price on the grant date		-			-
	Equal to market price on the grant date		502,586			60,000
	Less than market price on the grant date		-			-
	There were no option exercises during 2013 or 2012. The aggregate fair value of options vested during the years ended December 31, 2013 and 2012 was $279,000 and $600,000, respectively. As of December 31, 2013, the total unrecognized compensation expense related to non-vested stock option awards was $1.2 million, which is expected to be recognized over a weighted average term of approximately 2.5 years.
	CombiMatrix Molecular Diagnostics 2005 Stock Award Plan
	Our wholly owned subsidiary, CMDX, executed the CMDX Plan, with plan provisions and terms similar to that of the CombiMatrix Plan as described above. At December 31, 2013, there were 4.0 million authorized shares available under the CMDX Plan, with approximately 3.7 million shares available for grant. However, our Board of Directors has no intention of utilizing this plan in the future.
	The following is a summary of stock option activities for the CMDX Plan for 2013 and 2012:
		Shares			Weighted Average Price		Weighted Contractual Term (years)		Aggregate Intrinsic Value ('000s)
	Balance at December 31, 2011		411,000		$	0.36		4.2	$	60
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		(120,000	)	$	0.43
	Balance at December 31, 2012		291,000		$	0.34		3.1	$	51
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		-		$	-
	Balance at December 31, 2013		291,000		$	0.34		2.1	$	51
	Exercisable at December 31, 2012		241,000		$	0.3		3	$	50
	Exercisable at December 31, 2013		241,000		$	0.3		2.1	$	50
	There were no option grants during 2013 or 2012 under the CMDX Plan. The fair value of options vested during the years ended December 31, 2013 and 2012 was not significant. As of December 31, 2013, the total unrecognized compensation expense related to non-vested stock option awards was not significant.
	Stock Option Awards Granted to Non-Employees
	Stock option expense reflected in the consolidated statements of operations related to stock options issued to our non-employee scientific advisory board members and consultants are recognized at fair value using the Black-Scholes option-pricing model with weighted average assumptions as disclosed in Note 2 under “Stock-Based Compensation.” For the years ended December 31, 2013 and 2012, non-cash charges recognized from stock option awards granted to non-employees was not significant.

Note_12_Subsequent_Events

Note 12 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	12.     SUBSEQUENT EVENT
	From January 1, 2014 through the date of this report, certain investors have exercised Series A Warrants to purchase 124,111 shares of our common stock, resulting in net proceeds of $256,000 to us.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Accounting Principles and Fiscal Year End. The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”). We have a December 31 year-end.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	'
	Basis of Presentation and Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the years ended December 31, 2013 and 2012, net positive revenue adjustments were $607,000 and $570,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable.
	Clinical trials support services revenue is recognized when the related support services have been delivered to and accepted by the customer. Royalty revenue is recognized in the period when earned.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchaed with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statement of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		●	Level 1:	Observable market inputs such as quoted prices in active markets;
		●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, such as quoted prices for similar assets or liabilities; and
		●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash and money market funds within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables by payor class to assess our allowance at each period end. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor. Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.
Inventory Supplies, Policy [Policy Text Block]	'
	Supplies. Supplies inventory, which consists primarily of raw materials to be used in the production of the arrays we use for our tests, is stated at the lower of cost or market using the first-in, first-out method.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment. Property and equipment is recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Disposals are removed at cost less accumulated depreciation or amortization and any gain or loss from disposition is reflected in the consolidated statement of operations in the period of disposition. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Laboratory equipment (years)		3	to	5
	Furniture and fixtures (years)		5	to	7
	Computer hardware and software (years)			3
	Leasehold improvements		Lesser of lease term or useful life of improvement
	Certain leasehold improvements, furniture and equipment held under capital leases are classified as property and equipment and are amortized over their useful lives using the straight-line method. Lease amortization is included in depreciation expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation. The compensation cost for stock-based awards to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award), which is generally three years. The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.
	The weighted average assumptions used to estimate the fair value of awards granted for the periods presented are noted in the table below. Expected volatility is based on the separate historical volatility of the market prices of our common stock. The risk-free rate for the expected term, using the simplified method, of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
			For the Years Ended
			December 31,
			2013			2012
	Risk free interest rate			1.7	%		1.3	%
	Volatility			106	%		78.5	%
	Expected term (years)		6.3			6.3
	Expected dividends			0	%		0	%
	Stock-based compensation expense for 2013 and 2012 attributable to our functional expense categories were as follows (in thousands):
			For the Years Ended
			December 31,
			2013			2012
	Cost of products and services		$	7		$	5
	Research and development			-			7
	Sales and marketing			14			4
	General and administrative			411			386
	Total non-cash stock compensation		$	432		$	402
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenses. Prior to launching a new test or modifying an existing test, extensive laboratory validations consistent with the various regulations that govern our industry must be performed.  As a result, research and development expenses include labor, laboratory supplies, and other development costs required to maintain and improve our existing suite of diagnostic test offerings as well as to investigate and develop new tests.  Costs to acquire technologies which are utilized in research and development and which have no alternative future use are expensed when incurred. Software developed for use in our services is expensed as incurred until both (i) technological feasibility for the software has been established and (ii) all research and development activities for the other components of the system have been completed. We believe these criteria are met after we have received evaluations from third-party test sites and completed any resulting modifications to the services. Expenditures to date have been classified as research and development expense.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising. Costs associated with marketing and advertising of our services are expensed as incurred. For the years ended December 31, 2013 and 2012, we incurred marketing and advertising expenses of $249,000 and $312,000, respectively.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes. We recognize income taxes on an accrual basis based on tax positions taken or expected to be taken in our tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however.
Comprehensive Income, Policy [Policy Text Block]	'
	Other Comprehensive Loss. Components of comprehensive loss include unrealized gains and losses on available-for-sale securities and are included in the consolidated statements of comprehensive loss.
Segment Reporting, Policy [Policy Text Block]	'
	Segments. We have determined that we operate in one segment for financial reporting purposes.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase CombiMatrix stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
			For the Years Ended
			December 31,
			2013			2012
	Common stock options			639,019			161,933
	Common stock warrants			7,623,677			1,219,479
	Series A preferred stock convertible into common stock			-			822,431
	Series D preferred stock convertible into common stock			1,068,297			-
	Excluded dilutive securities			9,330,993			2,203,843
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements. In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Income Taxes (Topic 740), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” to eliminate diversity in practice. Under this ASU, an unrecognized tax benefit, or a portion of an unrecognized tax benefit that exists at the reporting date, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if certain criteria are met. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2013 with early adoption permitted. We do not believe the adoption of this ASU will have a material impact on our consolidated financial statements.
	In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income or loss on the respective line items in net income or loss. The new accounting guidance does not change the items that must be reported in other comprehensive income or loss or when an item of other comprehensive income or loss must be reclassified to net income or loss. The guidance is effective prospectively for fiscal years beginning after December 15, 2012 and we were required to adopt these new provisions during the first quarter of 2013. As the guidance requires additional presentation only, there was no impact to our consolidated results of operations or financial position.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Note 2 - Summary of Significant Accounting Policies (Tables) [Line Items]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		For the Years Ended
		December 31,
		2013			2012
	Risk free interest rate		1.7	%		1.3	%
	Volatility		106	%		78.5	%
	Expected term (years)	6.3			6.3
	Expected dividends		0	%		0	%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		For the Years Ended
		December 31,
		2013			2012
	Cost of products and services	$	7		$	5
	Research and development		-			7
	Sales and marketing		14			4
	General and administrative		411			386
	Total non-cash stock compensation	$	432		$	402
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		For the Years Ended
		December 31,
		2013			2012
	Common stock options		639,019			161,933
	Common stock warrants		7,623,677			1,219,479
	Series A preferred stock convertible into common stock		-			822,431
	Series D preferred stock convertible into common stock		1,068,297			-
	Excluded dilutive securities		9,330,993			2,203,843
Useful Lives [Member]	'
Note 2 - Summary of Significant Accounting Policies (Tables) [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
	Laboratory equipment (years)	3	to	5
	Furniture and fixtures (years)	5	to	7
	Computer hardware and software (years)		3
	Leasehold improvements	Lesser of lease term or useful life of improvement

Note_3_Cash_and_ShortTerm_Inve1

Note 3 - Cash and Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'
Cash, Cash Equivalents and Investments [Table Text Block]	'
		As of December 31, 2013
		Cost		Unrealized		Unrealized			Fair Value
				Gain		Loss
	Cash and money market securities	$	11,290	$	-	$	-		$	11,290
	Certificates of deposit		2,750		-		(4	)		2,746
		$	14,040	$	-	$	(4	)	$	14,036
	Included in cash and cash equivalents	$	12,290	$	-	$	(1	)	$	12,289
	Included in short-term investments		1,750		-		(3	)		1,747
		$	14,040	$	-	$	(4	)	$	14,036

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
					Fair Value Measurements
	31-Dec-13	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	8,263		$	7,264	$	999	$	-
	Short-term investments		1,747			-		1,747		-
	Total	$	10,010		$	7,264	$	2,746	$	-
	Liabilities:
	Derivative warrant liability	$	568		$	-	$	-	$	568
					Fair Value Measurements
	31-Dec-12	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	14		$	14	$	-	$	-
	Liabilities:
	Derivative warrant liability	$	4,483		$	-	$	-	$	4,483
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		Derivative Warrant Liability
	Balance, December 31, 2012	$	4,483
	Changes in fair value		(2,804	)
	Reclassifications		(1,111	)
	Balance, December 31, 2013	$	568

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables) (Components [Member])	12 Months Ended
	Dec. 31, 2013
Components [Member]	'
Note 5 - Property and Equipment (Tables) [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
		December 31,
		2013			2012
	Laboratory equipment		1,737		$	1,745
	Furniture and fixtures		225			103
	Computer hardware and software		42			214
	Leasehold improvements		279			289
			2,283			2,351
	Less - accumulated depreciation and amortization		(1,702	)		(1,685	)
		$	581		$	666

Note_6_Balance_Sheet_Component1

Note 6 - Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		December 31,
		2013		2012
	Accounts payable	$	636	$	610
	Payroll and other employee benefits		353		324
	Accrued vacation		144		143
	Deferred rent		-		4
	Royalties		211		106
	Other accrued expenses		23		35
		$	1,367	$	1,222

Note_7_Income_Taxes_Tables

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		December 31,
		2013			2012
	Deferred tax assets:
	Deferred settlement costs	$	1,215		$	1,574
	Stock-based compensation		423			428
	Accrued liabilities and other		500			485
	Net operating loss carryforwards and credits		61,756			59,173
	Total deferred tax assets		63,894			61,660
	Less: valuation allowance		(63,944	)		(61,620	)
	Deferred tax assets, net of valuation allowance		(50	)		40
	Deferred tax liabilities:
	Depreciation and amortization		50			(40	)
	Net deferred tax liability	$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		December 31,
		2013			2012
	Statutory federal tax rate		(34	%)		(34	%)
	Impact on state tax rates		(7	%)		(5	%)
	Warrant valuation		(22	%)		9	%
	Cancellation of vested non-qualified stock options		1	%		9	%
	Valuation allowance		59	%		20	%
	Other non deductible permanent items		3	%		1	%
			0	%		0	%

Note_8_Commitments_and_Conting1

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases of Lessee Disclosure [Table Text Block]	'
		Operating  Leases		Capital Leases			Total
	2014	$	161	$	188		$	349
	2015		13		43			56
	2016		-		25			25
	2017		-		3			3
	2018		-		-			-
	Total minimum lease payments	$	174		259		$	433
	Less- imputed interest				(26	)
	Present value of capital lease obligations				233
	Less- current portion				(168	)
	Capital lease obligations, net of current portion			$	65

Note_10_Stockholders_Equity_Ta

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Shares of Common Stock Issuable from Warrants
		Outstanding as of December 31,				Exercise
		2013		2012		Price			Expiration
	Liability-classified warrants:
	Oct-12		292,817		213,945		$2.06	-1	Apr-18
	Dec-12		-		724,825		$2.36		Jun-18
			292,817		938,770
	Equity-classified warrants:
	Dec-13		5,825,243		-		$3.12		Dec-18
	Jun-13		491,803		-		$3.55		Dec-18
	May-13		491,803		-		$3.77		Nov-18
	Mar-13		275,000		-		$3.49		Sep-18
	Apr-11		131,047		131,047		$21.40		Apr-16
	Oct-09		3,000		3,000		$77.80		Oct-14
	May-09		2,967		2,967	$75.00	-	90	May 2014 - July 2014
	May-09		109,997		109,997		$90.00		May-14
	Jul-08		-		33,698	$118.70	-	136.5	Jul-13
	Total		7,330,860		280,709
	Total - all warrants		7,623,677		1,219,479

Note_11_Stock_Options_Tables

Note 11 - Stock Options (Tables)	12 Months Ended
	Dec. 31, 2013
Options Granted [Member] | CombiMatrix Plan [Member]	'
Note 11 - Stock Options (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		December 31,
		2013			2012
	Weighted average fair values of options granted	$	2.39		$	6.23
	Options granted with exercise prices:
	Greater than market price on the grant date		-			-
	Equal to market price on the grant date		502,586			60,000
	Less than market price on the grant date		-			-
CombiMatrix Plan [Member]	'
Note 11 - Stock Options (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Shares			Weighted Average Price		Weighted Contractual Term (years)		Aggregate Intrinsic Value ('000s)
	Balance at December 31, 2011		223,243		$	48.69		7.8	$	6
	Granted		60,000		$	10
	Exercised		-		$	-
	Forfeited		(52,933	)	$	22.47
	Cancelled		(66,377	)	$	67.91
	Balance at December 31, 2012		163,933		$	35.21		7.3	$	23
	Granted		502,586		$	3.29
	Exercised		-		$	-
	Forfeited		(13,750	)	$	9.68
	Cancelled		(13,750	)	$	28.94
	Balance at December 31, 2013		639,019		$	10.79		8.7	$	1
	Exercisable at December 31, 2012		86,335		$	53.44		5.7	$	-
	Exercisable at December 31, 2013		98,259		$	47.75		6	$	-
CMDX Plan [Member]	'
Note 11 - Stock Options (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Shares			Weighted Average Price		Weighted Contractual Term (years)		Aggregate Intrinsic Value ('000s)
	Balance at December 31, 2011		411,000		$	0.36		4.2	$	60
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		(120,000	)	$	0.43
	Balance at December 31, 2012		291,000		$	0.34		3.1	$	51
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		-		$	-
	Balance at December 31, 2013		291,000		$	0.34		2.1	$	51
	Exercisable at December 31, 2012		241,000		$	0.3		3	$	50
	Exercisable at December 31, 2013		241,000		$	0.3		2.1	$	50

Note_1_Description_of_Business1

Note 1 - Description of Business (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Disclosure Text Block [Abstract]	'
Cash, Cash Equivalents, and Short-term Investments	$14,040

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%	'
Net Revenue Adjustments	$607,000	$570,000
Marketing and Advertising Expense	$249,000	$312,000
Minimum [Member]	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'
Equity Method Investment, Ownership Percentage	20.00%	'
Maximum [Member]	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'
Equity Method Investment, Ownership Percentage	50.00%	'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Property and Equipment - Estimated Useful Lives	12 Months Ended
	Dec. 31, 2013
Laboratory Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, estimated useful life	'5 years
Laboratory Equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, estimated useful life	'3 years
Laboratory Equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, estimated useful life	'5 years
Furniture and Fixtures [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, estimated useful life	'5 years
Furniture and Fixtures [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, estimated useful life	'7 years
Computer Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, estimated useful life	'3 years
Leasehold Improvements [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Leasehold improvements	'Lesser of lease term or useful life of improvement

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Share-based Compensation - Assumptions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation - Assumptions [Abstract]	'	'
Risk free interest rate	1.70%	1.30%
Volatility	106.00%	78.50%
Expected term (years)	'6 years 109 days	'6 years 109 days
Expected dividends	0.00%	0.00%

Note_2_Summary_of_Significant_5

Note 2 - Summary of Significant Accounting Policies (Details) - Stock-Based Compensation by Functional Expense Categories (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$432	$402
Cost of Sales [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	7	5
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	'	7
Selling and Marketing Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	14	4
General and Administrative Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$411	$386

Note_2_Summary_of_Significant_6

Note 2 - Summary of Significant Accounting Policies (Details) - Anti-dilutive Securities	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	9,330,993	2,203,843
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	639,019	161,933
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	7,623,677	1,219,479
Series A Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	'	822,431
Series D Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	1,068,297	'

Note_3_Cash_and_ShortTerm_Inve2

Note 3 - Cash and Short-Term Investments (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 3 - Cash and Short-Term Investments (Details) [Line Items]	'
Cash and Cash Equivalents, at Carrying Value	$12,290
Investments, Fair Value Disclosure	1,747
Short-term Investments [Member]	'
Note 3 - Cash and Short-Term Investments (Details) [Line Items]	'
Investments, Fair Value Disclosure	$1,747

Note_3_Cash_and_ShortTerm_Inve3

Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'
Cash and Cash Equivalents, Cost	$14,040	'	'
Cash and Cash Equivalents, Unrealized Loss	-4	'	'
Cash and Cash Equivalents, Fair Value	14,036	'	'
Included in cash and cash equivalents	12,290	'	'
Included in cash and cash equivalents	-1	'	'
Included in cash and cash equivalents	12,289	2,372	6,385
Included in short-term investments	1,747	'	'
Short-term Investments [Member]	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'
Included in short-term investments	1,750	'	'
Included in short-term investments	-3	'	'
Included in short-term investments	1,747	'	'
Cash and Money Market Securities [Member]	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'
Cash and Cash Equivalents, Cost	11,290	'	'
Cash and Cash Equivalents, Fair Value	11,290	'	'
Certificates of Deposit [Member]	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'
Cash and Cash Equivalents, Cost	2,750	'	'
Cash and Cash Equivalents, Unrealized Loss	-4	'	'
Cash and Cash Equivalents, Fair Value	$2,746	'	'

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Financial Assets Measured on a Recurring Basis (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets:	'	'
Cash equivalents	$8,263	$14
Short-term investments	1,747	'
Total	10,010	'
Liabilities:	'	'
Derivative warrant liability	568	4,483
Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Cash equivalents	7,264	14
Total	7,264	'
Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Cash equivalents	999	'
Short-term investments	1,747	'
Total	2,746	'
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities:	'	'
Derivative warrant liability	$568	$4,483

Note_4_Fair_Value_Measurements3

Note 4 - Fair Value Measurements (Details) - Financial Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Financial Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs [Abstract]	'
Balance	$4,483
Changes in fair value	-2,804
Reclassifications	-1,111
Balance	$568

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation, Depletion and Amortization	$352,000	$276,000
Capital Leases, Balance Sheet, Assets by Major Class, Net	$246,000	$523,000

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment (Details) - Components of Property and Equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$2,283	$2,351
Less - accumulated depreciation and amortization	-1,702	-1,685
	581	666
Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	1,737	1,745
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	225	103
Computer Hardware and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	42	214
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$279	$289

Note_6_Balance_Sheet_Component2

Note 6 - Balance Sheet Components (Details) - Accounts Payable, Accrued Expenses and Other Accrued Expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts Payable, Accrued Expenses and Other Accrued Expenses [Abstract]	'	'
Accounts payable	$636	$610
Payroll and other employee benefits	353	324
Accrued vacation	144	143
Deferred rent	'	4
Royalties	211	106
Other accrued expenses	23	35
	$1,367	$1,222

Note_7_Income_Taxes_Details

Note 7 - Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Deferred Tax Assets, Gross	$63,894,000	$61,660,000
Operating Loss Carryforwards	160,000,000	'
Tax Credit Carryforward, Amount	$5,200,000	'

Note_7_Income_Taxes_Details_De

Note 7 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Deferred settlement costs	$1,215	$1,574
Stock-based compensation	423	428
Accrued liabilities and other	500	485
Net operating loss carryforwards and credits	61,756	59,173
Total deferred tax assets	63,894	61,660
Less: valuation allowance	-63,944	-61,620
Deferred tax assets, net of valuation allowance	-50	40
Deferred tax liabilities:	'	'
Depreciation and amortization	$50	($40)

Note_7_Income_Taxes_Details_Re

Note 7 - Income Taxes (Details) - Reconciliation of Income Tax Rate	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Income Tax Rate [Abstract]	'	'
Statutory federal tax rate	-34.00%	-34.00%
Impact on state tax rates	-7.00%	-5.00%
Warrant valuation	-22.00%	9.00%
Cancellation of vested non-qualified stock options	1.00%	9.00%
Valuation allowance	59.00%	20.00%
Other non deductible permanent items	3.00%	1.00%
	0.00%	0.00%

Note_8_Commitments_and_Conting2

Note 8 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	sqft
Note 8 - Commitments and Contingencies (Details) [Line Items]	'	'
Area of Real Estate Property (in Square Feet)	12,200	'
Capital Leased Assets, Number of Units	11	'
Capital Leases, Original Purchase Amounts	$435,000	'
Capital Lease Obligations	259,000	'
Capital Lease Obligations, Weighted Average Interest Rate	13.50%	'
Operating Leases, Rent Expense	297,000	302,000
Litigation Settlement Percentage	12.50%	'
Maximum Annual Litigation Payment	1,500,000	'
Minimum Quarterly Litigation Payment	25,000	'
Royalty Expense	$100,000	$100,000
Laboratory Equipment [Member]	'	'
Note 8 - Commitments and Contingencies (Details) [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'5 years	'

Note_8_Commitments_and_Conting3

Note 8 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Future Minimum Lease Payments [Abstract]	'	'
2014	$161	'
2014	188	'
2014	349	'
2015	13	'
2015	43	'
2015	56	'
2016	25	'
2016	25	'
2017	3	'
2017	3	'
Total minimum lease payments	174	'
Total minimum lease payments	259	'
Total minimum lease payments	433	'
Less- imputed interest	-26	'
Present value of capital lease obligations	233	'
Less- current portion	-168	-253
Capital lease obligations, net of current portion	$65	$226

Note_10_Stockholders_Equity_De

Note 10 - Stockholders' Equity (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

10 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

10 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Mar. 19, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 19, 2013

Mar. 19, 2013

Mar. 19, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2012

Jun. 28, 2013

Sep. 30, 2012

Sep. 30, 2012

Nov. 29, 2012

Jun. 28, 2013

Nov. 29, 2012

Sep. 30, 2012

Nov. 29, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 28, 2013

Mar. 20, 2013

Nov. 29, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 28, 2013

Mar. 20, 2013

Mar. 19, 2013

Mar. 19, 2013

Jun. 28, 2013

Dec. 31, 2013

Jan. 04, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2012

Dec. 31, 2013

Mar. 19, 2013

Mar. 19, 2013

Mar. 19, 2013

Dec. 31, 2013

Dec. 31, 2013

3-May-13

Jun. 28, 2013

Jun. 28, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 24, 2014

Dec. 31, 2013

Mar. 31, 2013

Fixed Combination [Member]

Potentially Increased [Member]

Upon Conversion of All Shares [Member]

Net of Offering Costs [Member]

Net [Member]

Deemed Dividend From Issuing Stock [Member]

Deemed Dividend From Issuing Stock [Member]

First Closing [Member]

First Closing [Member]

First Closing [Member]

First Closing [Member]

First Closing [Member]

First Closing [Member]

Second Closing [Member]

Second Closing [Member]

Second Closing [Member]

Second Closing [Member]

Net [Member]

Additional [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series C Warrant [Member]

Series D Warrant [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Purchase Agreement [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Amortization of Deferred Offering Costs [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series D Convertible Preferred Stock [Member]

First Closing [Member]

Series A Convertible Preferred Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series C Warrant [Member]

Series A Convertible Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Warrants [Member]

Series C Warrant [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Warrants [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Series A Warrants [Member]

Maximum [Member]

Note 10 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,050.70

'

'

'

'

1,449.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

6.00%

'

'

'

6.00%

'

'

6.00%

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Issued During Period, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Convertible Preferred Stock (in Dollars)

'

'

'

'

'

'

$10,700,000

$12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,079,000

'

'

'

'

$1,800,000

'

'

$1,769,000

'

'

$2,140,000

$2,139,000

'

'

$10,892,000

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.00

'

'

'

'

'

'

'

$2.86

$2.86

'

$2.06

'

$2.06

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,644.45

'

855.54814

'

'

'

'

'

'

'

'

'

'

'

'

9,799.30

'

'

'

Make Whole Payment, Per Share (in Dollars per share)

'

$118

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Stated Value (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

528,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,209,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

822,421

'

427,878

'

'

'

'

'

'

535,392

'

'

'

'

839,864

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,871

'

'

'

130,000

'

1,610.40

'

'

1,200

1,200

'

'

'

'

12,000

'

Dividends, Preferred Stock, Stock (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Dividends, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,164

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Dividends, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,307

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends, Preferred Stock (in Dollars)

'

'

'

'

'

'

'

'

123,000

617,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

247,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

171

'

'

'

'

'

'

'

213,945

'

491,803

'

'

724,825

491,803

'

'

'

'

'

81,910

81,910

'

470,907

'

'

'

'

'

'

117,231

666,375

275,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

485.4369

'

485.4369

'

Warrants, Term

'

'

'

'

'

'

'

'

'

'

'

'

'5 years 6 months

'

'

'

'5 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years 6 months

'

'5 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'5 years

'

Warrants, Exercisable Term

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

3.05

'

'

'

'

'

'

'

'

9.5

3.77

'

'

2.364

3.55

'

'

'

'

'

2.06

2.06

'

2.86

3.05

'

'

'

'

'

2.85759

'

3.49

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.12

'

3.12

'

Proceeds from Warrant Exercises (in Dollars)

'

3,142,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years 109 days

'

'

'

'

'

'

'

'5 years

'5 years 109 days

'

'5 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

114.50%

65.60%

126.50%

103.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.80%

0.70%

1.40%

0.80%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Fair Value, Amount Not Offset Against Collateral (in Dollars)

'

'

'

'

'

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

'

'

4,500,000

'

'

4,500,000

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Gain on Derivative (in Dollars)

'

'

'

'

'

'

'

'

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

2,400,000

'

2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Other (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Residual Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

495,000

'

'

495,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issuance Costs (in Dollars)

'

'

527,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

427,000

'

'

427,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

101,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Other (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

147,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense (in Dollars)

'

356,000

179,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

280,000

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.05

$3.05

'

'

$1,000

$1,000

$1,000

'

$1,000

'

$1,000

'

PeriodFollowingTheClosing

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$417,000

'

'

'

'

'

$1,200,000

'

'

'

'

'

Percent of Outstanding Common Stock

'

'

'

'

9.99%

19.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,825,243

'

'

'

'

'

'

'

'

'

'

'

'

'

839,864

839,864

'

5,825,243

'

5,825,243

'

Fair Value Inputs, Discount Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,756,946

1,068,297

'

'

Note_10_Stockholders_Equity_De1

Note 10 - Stockholders' Equity (Details) - Outstanding Warrants (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	7,623,677		1,219,479
October 2012 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	292,817		213,945
Exercise Price (in Dollars per share)	$2.06	[1]	'
Expiration	30-Apr-18		'
December 2012 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	'		724,825
Exercise Price (in Dollars per share)	$2.36		'
Expiration	30-Jun-18		'
Liability-classified Warrants [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	292,817		938,770
December 2013 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	5,825,243		'
Exercise Price (in Dollars per share)	$3.12		'
Expiration	31-Dec-18		'
June 2013 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	491,803		'
Exercise Price (in Dollars per share)	$3.55		'
Expiration	31-Dec-18		'
May 2013 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	491,803		'
Exercise Price (in Dollars per share)	$3.77		'
Expiration	30-Nov-18		'
March 2013 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	275,000		'
Exercise Price (in Dollars per share)	$3.49		'
Expiration	30-Sep-18		'
April 2011 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	131,047		131,047
Exercise Price (in Dollars per share)	$21.40		'
Expiration	30-Apr-16		'
October 2009 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	3,000		3,000
Exercise Price (in Dollars per share)	$77.80		'
Expiration	31-Oct-14		'
May 2009 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	2,967		2,967
Expiration	31-Jul-14		'
May 2009 [Member] | Minimum [Member]	'		'
Liability-classified warrants:	'		'
Exercise Price (in Dollars per share)	$75		'
May 2009 [Member] | Maximum [Member]	'		'
Liability-classified warrants:	'		'
Exercise Price (in Dollars per share)	$90		'
May 2009 II [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	109,997		109,997
Exercise Price (in Dollars per share)	$90		'
Expiration	31-May-14		'
July 2008 [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	'		33,698
Expiration	31-Jul-13		'
July 2008 [Member] | Minimum [Member]	'		'
Liability-classified warrants:	'		'
Exercise Price (in Dollars per share)	$118.70		'
July 2008 [Member] | Maximum [Member]	'		'
Liability-classified warrants:	'		'
Exercise Price (in Dollars per share)	$136.50		'
Equity-classified Warrants [Member]	'		'
Liability-classified warrants:	'		'
Shares of Common Stock Issuable From Warrants Outstanding	7,330,860		280,709
[1]	Prior to the anti-dilution adjustments which occurred on March 20, 2013, June 28, 2013 and December 20, 2013, these warrants had an initial exercise price of $9.50 per share.

Note_11_Stock_Options_Details

Note 11 - Stock Options (Details) (USD $)	12 Months Ended				12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 13, 2013
			CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	CMDX Plan [Member]
			Initial [Member]	Additional [Member]			Minimum [Member]	Maximum [Member]
Note 11 - Stock Options (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Exercise Price, Percent of Fair Market Value	'	'	100.00%	100.00%	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'3 years	'4 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'6 years 109 days	'6 years 109 days	'	'	'10 years	'	'	'	'
Authorized Increase	'	'	'	'	3.00%	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	856,000	'	'	'	4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	203,000	'	'	'	3,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	'	'	'	'	$279,000	$600,000	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	'	'	'	'	$1,200,000	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'	'	'2 years 6 months	'	'	'	'

Note_11_Stock_Options_Details_

Note 11 - Stock Options (Details) - Stock Option Activities #1 (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 11 - Stock Options (Details) - Stock Option Activities #1 [Line Items]	'	'	'
Granted	502,586,000	60,000,000	'
CombiMatrix Corporation 2006 Stock Incentive Plan [Member]	'	'	'
Note 11 - Stock Options (Details) - Stock Option Activities #1 [Line Items]	'	'	'
Balance	163,933	'	223,243
Balance	$35.21	'	$48.69
Balance	'8 years 255 days	'7 years 109 days	'7 years 292 days
Balance	$1	$23	$6
Exercisable	98,259	86,335	'
Exercisable	$47.75	$53.44	'
Exercisable	'6 years	'5 years 255 days	'
Granted	502,586	60,000	'
Granted	$3.29	$10	'
Forfeited	-13,750	-52,933	'
Forfeited	$9.68	$22.47	'
Cancelled	-13,750	-66,377	'
Cancelled	$28.94	$67.91	'
Balance	639,019	163,933	'
Balance	$10.79	$35.21	'

Note_11_Stock_Options_Details_1

Note 11 - Stock Options (Details) - Options Granted (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Options Granted [Abstract]	'	'
Weighted average fair values of options granted	$2.39	$6.23
Options granted with exercise prices:	'	'
Equal to market price on the grant date	502,586	60,000

Note_11_Stock_Options_Details_2

Note 11 - Stock Options (Details) - Stock Option Activities #2 (CMDX Plan [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CMDX Plan [Member]	'	'	'
Note 11 - Stock Options (Details) - Stock Option Activities #2 [Line Items]	'	'	'
Balance	291,000	'	411,000
Balance	$0.34	'	$0.36
Balance	'2 years 36 days	'3 years 36 days	'4 years 73 days
Balance	$51	$51	$60
Exercisable	241,000	241,000	'
Exercisable	$0.30	$0.30	'
Exercisable	'2 years 36 days	'3 years	'
Exercisable	$50	$50	'
Cancelled	'	-120,000	'
Cancelled	'	$0.43	'
Balance	291,000	291,000	'
Balance	$0.34	$0.34	'

Note_12_Subsequent_Events_Deta

Note 12 - Subsequent Events (Details) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2013	Mar. 24, 2014
		Subsequent Event [Member]
Note 12 - Subsequent Events (Details) [Line Items]	'	'
Stock Issued During Period, Shares, Conversion of Units	'	124,111
Proceeds from Warrant Exercises	$3,142,000	$256,000